Browse Drug Recalls
1,681 FDA drug safety recalls.
FDA Drug Recall Enforcement Database
Browse 1,681 FDA drug recall enforcement actions. Each entry includes the product description, reason for recall, classification (Class I through III based on severity), recalling firm, and distribution details. Use the filters below to search by year, classification, state, or keyword.
Drug Safety Recalls
Browse 1,681 FDA drug recalls in 2018.
| Date | Product | Reason | Class | Firm |
|---|---|---|---|---|
| Jul 20, 2018 | Dr. King's Natural Medicine Homeopathic Heavy Metal Detox, 2 fl. oz. (59 mL),... | Microbial contamination | Class I | King Bio Inc. |
| Jul 20, 2018 | Dr. King's Natural Medicine Homeopathic Climate Adaptation Cold & Damp, 2 fl.... | Microbial contamination | Class I | King Bio Inc. |
| Jul 20, 2018 | Dr. King's SafeCare Rx Gout Symptom Relief, 2 fl. oz. (59 mL), King Bio, Inc.... | Microbial contamination | Class I | King Bio Inc. |
| Jul 20, 2018 | Dr. King's SafeCare Rx Smoke Control, 2 fl. oz. (59 mL), King Bio, Inc., 3 We... | Microbial contamination | Class I | King Bio Inc. |
| Jul 20, 2018 | Dr. King's SafeCare Rx CS-Lymph Hodgkins, 2 fl. oz. (59 mL), King Bio, Inc., ... | Microbial contamination | Class I | King Bio Inc. |
| Jul 20, 2018 | Dr. King's SafeCare Rx LymePlex, 2 fl. oz. (59 mL), King Bio, Inc., 3 Westsid... | Microbial contamination | Class I | King Bio Inc. |
| Jul 18, 2018 | Unit Dose Valsartan Tablets, USP, 80 mg. Rx only, Distributed by: Major Phar... | CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product. | Class II | MAJOR PHARMACEUTICALS |
| Jul 18, 2018 | AvKARE Valsartan and Hydrochlorothiazide 320 mg/12.5 mg tablets, 90-count bot... | CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product. | Class II | Avkare Incorporated |
| Jul 18, 2018 | Valsartan HCTZ, 160/12.5mg, 30 tablets per bottle, Rx Only, Repackaged By: No... | CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product. | Class II | Northwind Pharmaceuticals LLC |
| Jul 18, 2018 | AvKARE Valsartan and Hydrochlorothiazide 160 mg/25 mg tablets, 90-count bottl... | CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product. | Class II | Avkare Incorporated |
| Jul 18, 2018 | Valsartan, 320mg, 30 tablets per bottle, Rx Only, Repackaged By: Northwind Ph... | CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product. | Class II | Northwind Pharmaceuticals LLC |
| Jul 18, 2018 | AvKARE Valsartan and Hydrochlorothiazide 160 mg/12.5 mg tablets, 90-count bot... | CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product. | Class II | Avkare Incorporated |
| Jul 18, 2018 | Indomethacin Capsules, USP, 50 mg, 100-count bottles, Rx only, Manufactured f... | Failed Tablet/Capsule Specifications: customer complaints of deformed, clumped, misshaped, melted... | Class II | Hetero Labs, Ltd. - Unit III |
| Jul 18, 2018 | Valsartan, 80mg, 30 tablets per bottle, Rx Only, Repackaged By: Northwind Pha... | CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product. | Class II | Northwind Pharmaceuticals LLC |
| Jul 18, 2018 | Potassium Citrate Extended-Release Tablets, USP, 10 mEq, 100-count bottles, R... | Failed Tablet/Capsule Specifications: Tablet breakage | Class II | VENSUN PHARMACEUTICALS INC |
| Jul 18, 2018 | AvKARE Valsartan and Hydrochlorothiazide 80 mg/12.5 mg tablets, 90-count bott... | CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product. | Class II | Avkare Incorporated |
| Jul 18, 2018 | Valsartan, 160 mg, 30 tablets per bottle, Rx Only, Repackaged By: Northwind P... | CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product. | Class II | Northwind Pharmaceuticals LLC |
| Jul 18, 2018 | AvKARE Valsartan and Hydrochlorothiazide 320 mg/25 mg tablets 90-count bottle... | CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product. | Class II | Avkare Incorporated |
| Jul 18, 2018 | Unit Dose Valsartan Tablets, USP. 160 mg. Rx only.,Distributed by: Major Pha... | CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product. | Class II | MAJOR PHARMACEUTICALS |
| Jul 18, 2018 | Potassium Citrate Extended-Release Tablets, USP, 15 mEq, 100-count bottles, R... | Failed Tablet/Capsule Specifications: Tablet breakage | Class II | VENSUN PHARMACEUTICALS INC |
| Jul 17, 2018 | Valsartan/HCTZ 320mg/12.5 mg tablet, 90-count bottle, Rx only, RemedyRepack, ... | CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product. | Class II | RemedyRepack Inc. |
| Jul 17, 2018 | Valsartan and Hydrochlorothiazide Tablets, Valsartan 320 MG and Hydrochloroth... | CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product. | Class II | A-S Medication Solutions LLC. |
| Jul 17, 2018 | Valsartan Tablets, 80 MG, 30-count bottle (NDC 54569-6582-0, 90-count bottle ... | CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product. | Class II | A-S Medication Solutions LLC. |
| Jul 17, 2018 | Valsartan and Hydrochlorothiazide Tablets, Valsartan 160 MG and Hydrochloroth... | CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product. | Class II | A-S Medication Solutions LLC. |
| Jul 17, 2018 | Valsartan Tablets, 160 MG, 30-count bottle (NDC 54569-6583-0), 90-count bottl... | CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product. | Class II | A-S Medication Solutions LLC. |
| Jul 17, 2018 | Valsartan/HCTZ 160 mg/12.5 mg tablet, 90-count bottle, Rx only, RemedyRepack,... | CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product. | Class II | RemedyRepack Inc. |
| Jul 17, 2018 | Emergency First Aid Eyewash (Purified Water 98.3%), packaged in a) 4fl oz. (... | CGMP Deviations | Class II | Longbow First Aid Products Manufactory |
| Jul 17, 2018 | Eyewash Purified water 98.3%, Ophthalmic Solution, packaged in a) 4 FL OZ (ND... | CGMP Deviations | Class II | Longbow First Aid Products Manufactory |
| Jul 16, 2018 | Valsartan and Hydrochlorothiazide (HCTZ) Tablets, USP 160 mg/12.5 mg tablets,... | CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product. | Class II | Teva Pharmaceuticals USA |
| Jul 16, 2018 | Valsartan Tablets, USP 160 mg, 90-count bottle (NDC 0591-2169-19), 1000-count... | CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product. | Class II | Teva Pharmaceuticals USA |
| Jul 16, 2018 | Valsartan and Hydrochlorothiazide (HCTZ) Tablets, USP 160 mg/25 mg tablets, U... | CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product. | Class II | Teva Pharmaceuticals USA |
| Jul 16, 2018 | Valsartan Tablets, USP 320 mg, 90-count bottle (NDC 0591-2170-19), 500-count ... | CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product. | Class II | Teva Pharmaceuticals USA |
| Jul 16, 2018 | Valsartan and Hydrochlorothiazide (HCTZ) Tablets, USP 80 mg/12.5 mg tablets, ... | CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product. | Class II | Teva Pharmaceuticals USA |
| Jul 16, 2018 | Omega-3-Acid Ethyl Esters Capsules USP, 1 gram* 120-count bottle Rx Only. Ma... | API material used in the manufacturing of the product did not receive regulatory approval prior t... | Class II | Teva Pharmaceuticals USA |
| Jul 16, 2018 | Valsartan Tablets, USP 40 mg, 30-count bottle (NDC 0591-2167-30), 90-count bo... | CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product. | Class II | Teva Pharmaceuticals USA |
| Jul 16, 2018 | Valsartan Tablets, USP 80 mg, 90-count bottle (NDC 0591-2168-19), 1000-count ... | CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product. | Class II | Teva Pharmaceuticals USA |
| Jul 16, 2018 | Valsartan and Hydrochlorothiazide (HCTZ) Tablets, USP 320 mg/12.5 mg tablets,... | CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product. | Class II | Teva Pharmaceuticals USA |
| Jul 16, 2018 | Valsartan and Hydrochlorothiazide (HCTZ) Tablets, USP 320 mg/25 mg tablets, U... | CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product. | Class II | Teva Pharmaceuticals USA |
| Jul 13, 2018 | Solco Healthcare US Valsartan and Hydrochlorothiazide, USP, 160 MG/25 MG Tabl... | CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product. | Class II | Prinston Pharmaceutical Inc |
| Jul 13, 2018 | Solco Healthcare US Valsartan and Hydrochlorothiazide, USP, 320 MG/25 MG Tabl... | CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product. | Class II | Prinston Pharmaceutical Inc |
| Jul 13, 2018 | Solco Healthcare US Valsartan, USP, 320 MG Tablets, 90-count bottle,Rx Only M... | CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product. | Class II | Prinston Pharmaceutical Inc |
| Jul 13, 2018 | Solco Healthcare US Valsartan, USP, 80 MG Tablets, 90-count bottle, Rx Only M... | CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product. | Class II | Prinston Pharmaceutical Inc |
| Jul 13, 2018 | Solco Healthcare US Valsartan, USP, 160 MG Tablets, 90-count bottles, Rx Only... | CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product. | Class II | Prinston Pharmaceutical Inc |
| Jul 13, 2018 | Solco Healthcare US Valsartan, USP, 40 MG Tablets, 30- count bottle, Rx Only,... | CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product. | Class II | Prinston Pharmaceutical Inc |
| Jul 13, 2018 | Solco Healthcare US Valsartan and Hydrochlorothiazide, USP, 320 MG/12.5 MG Ta... | CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product. | Class II | Prinston Pharmaceutical Inc |
| Jul 13, 2018 | Solco Healthcare US Valsartan and Hydrochlorothiazide, USP, 160 MG/12.5 MG Ta... | CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product. | Class II | Prinston Pharmaceutical Inc |
| Jul 13, 2018 | Solco Healthcare US Valsartan and Hydrochlorothiazide, USP, 80 MG/12.5 MG Tab... | CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product. | Class II | Prinston Pharmaceutical Inc |
| Jul 12, 2018 | Testosterone Cypionate Injection, USP, 200 mg/mL, Rx only, 10 mL vials, Distr... | Presence of Particulate Matter: organic and inorganic compounds detected in vials of product. | Class II | Sun Pharmaceutical Industries, Inc. |
| Jul 11, 2018 | Fluconazole Injection, USP, Iso-Osmotic Sodium Chloride Diluent, 200 mg in 10... | Superpotent Drug: lots out of specification for elevated sodium chloride and fluconazole assay. | Class III | Renaissance Lakewood, LLC |
| Jul 11, 2018 | Fluconazole Injection, USP, Iso-Osmotic Sodium Chloride Diluent, 400 mg in 20... | Superpotent Drug and Failed Stability Specifications: lot out of specification for elevated sodiu... | Class III | Renaissance Lakewood, LLC |
Frequently Asked Questions
When a drug safety issue is identified — through FDA inspections, laboratory testing, adverse event reports, or manufacturer quality checks — the responsible company issues a recall to remove the affected products from the market. Pharmacies pull the product from shelves, and consumers are advised to contact their healthcare provider for alternatives.
The leading causes include cGMP deviations, impurity contamination (including nitrosamines like NDMA), failed dissolution or stability testing, sterility issues, potency problems, labeling errors, and foreign particle contamination.
Use the search and filter tools on this page to look up specific medications, active ingredients, or manufacturers. Each recall entry includes the product description, lot numbers, and distribution details.